

Ashraf Badros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10910743/publications.pdf>

Version: 2024-02-01

35
papers

5,388
citations

249298

26
h-index

425179

34
g-index

36
all docs

36
docs citations

36
times ranked

5009
citing authors

#	ARTICLE	IF	CITATIONS
1	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
2	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. <i>Cancer</i> , 2021, 127, 4198-4212.	2.0	89
3	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	5.1	544
4	Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 732-739.	0.8	88
5	Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1355-1365.	3.2	116
6	Improvement of Painful Bortezomib-Induced Peripheral Neuropathy Following Acupuncture Treatment in a Case Series of Multiple Myeloma Patients. <i>Medical Acupuncture</i> , 2012, 24, 181-187.	0.3	10
7	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
8	Role of carfilzomib in the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2012, 5, 361-372.	1.0	16
9	Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. <i>Blood</i> , 2011, 117, 788-797.	0.6	148
10	Acupuncture Treatment for Bortezomib-Induced Peripheral Neuropathy: A Case Report. <i>Pain Research and Treatment</i> , 2011, 2011, 1-4.	1.7	36
11	In the Age of Novel Therapies, What Defines High-Risk Multiple Myeloma?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-28-S-34.	2.3	9
12	Osteonecrosis of the Jaw. , 2010, , 133-149.		0
13	Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 5250-5257.	3.2	228
14	A novel bioassay model to determine clinically significant bisphosphonate levels. <i>Supportive Care in Cancer</i> , 2009, 17, 1553-1557.	1.0	55
15	Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. <i>British Journal of Haematology</i> , 2009, 144, 667-676.	1.2	126
16	Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5904-5909.	0.8	139
17	Thalidomide in Patients with Relapsed Multiple Myeloma. , 2008, , 205-227.		0
18	Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature. <i>Cancer</i> , 2007, 110, 1042-1049.	2.0	213

#	ARTICLE	IF	CITATIONS
19	Phase I Trial of First-Line Bortezomib/Thalidomide plus Chemotherapy for Induction and Stem Cell Mobilization in Patients with Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 210-216.	1.4	42
20	Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors. <i>Journal of Clinical Oncology</i> , 2006, 24, 945-952.	0.8	517
21	Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. <i>Nature Medicine</i> , 2005, 11, 1230-1237.	15.2	282
22	Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait. <i>Clinical Advances in Hematology and Oncology</i> , 2005, 3, 916-7; discussion 918.	0.3	7
23	Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. <i>Experimental Hematology</i> , 2003, 31, 73-80.	0.2	91
24	Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. <i>Blood</i> , 2003, 101, 3849-3856.	0.6	123
25	Thalidomide Paradoxical Effect on Concomitant Multiple Myeloma and Myelodysplasia. <i>Leukemia and Lymphoma</i> , 2002, 43, 1267-1271.	0.6	11
26	Reduced Intensity Conditioning and Allogeneic Stem-Cell Transplantation: Determining Its Role in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2002, 20, 4268-4269.	0.8	5
27	Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2002, 20, 1295-1303.	0.8	145
28	ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. <i>Transfusion</i> , 2002, 42, 205-209.	0.8	43
29	Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. <i>British Journal of Haematology</i> , 2002, 117, 103-108.	1.2	133
30	Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. <i>Blood</i> , 2001, 98, 1614-1615.	0.6	469
31	High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. <i>Blood</i> , 2001, 97, 2574-2579.	0.6	177
32	Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. <i>British Journal of Haematology</i> , 2001, 114, 600-607.	1.2	199
33	Results of autologous stem cell transplant in multiple myeloma patients with renal failure. <i>British Journal of Haematology</i> , 2001, 114, 822-829.	1.2	267
34	Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma. <i>Cancer</i> , 2001, 91, 900-908.	2.0	23
35	Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. <i>Blood</i> , 2000, 95, 4008-4010.	0.6	290